Rhythm Pharmaceuticals Inc at Guggenheim Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Seamus Fernandez - Guggenheim Securities - Analyst : David, maybe just to kind of start us off high level, you've been CEO of Rhythm for quite some time, developed a robust portfolio of assets. But I think there's a separation between treatment of rare obesity and how people think about obesity, sort of writ large in the context of the GLP-1 space. Maybe just bring us into the Rhythm approach to treating rare obesity.

Question: Seamus Fernandez - Guggenheim Securities - Analyst : We just had, in terms of building up Bardet-Biedl, one of the things that I think maybe the market was a little bit confused by some fits and starts in terms of the sales progression. But I think there's a good understanding that there's a steady state sales progression for Bardet-Biedl. We're getting a better understanding of hypothalamic obesity, and I think part of that was some data that was just presented. Can you to talk a little bit about those data and your conviction in hypothalamic obesity and the size of that market opportunity as well?

Question: Seamus Fernandez - Guggenheim Securities - Analyst : So that kind of brings us to another opportunity which would be the DAYBREAK data and additional sort of genetic abnormalities. Can you talk a little bit about those data and the path to really developing that additional market?

Question: Seamus Fernandez - Guggenheim Securities - Analyst : Great. And one of the things that -- I think we've both been doing this a long time. You've been doing a little bit longer than I and that's not a comment on anything, other than --

Question: Seamus Fernandez - Guggenheim Securities - Analyst : But one of the things that I think is really evident is that ability to grow the rare disease population over time in the global marketplace. Maybe you can just remind everybody what that looks like because I think that's a critically important piece of the story from an upside perspective. It isn't just did we get the epi right in the U.S., did we get the epi right in Europe. It's did we get the epi right globally, and that's a totally different question I think. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 11, 2024 / 4:30PM, RYTM.OQ - Rhythm Pharmaceuticals Inc at Guggenheim Global Healthcare Conference

Question: Seamus Fernandez - Guggenheim Securities - Analyst : Brick-by-brick strategy. So, let's talk about the pipeline and the sort of evolution of Rhythm from here beyond IMCIVREE. So, first just address potential concerns around 2032 patent expiration and the possibility or a threat of generic competition as a starting point and then how the pipeline can be a meaningful sort of extension of IMCIVREE's future.

Question: Seamus Fernandez - Guggenheim Securities - Analyst : And the pace in the path to the DAYBREAK opportunity, is that something that you would say, okay, this is something we'll build that will will will approach that opportunity with setmelanotide? Or is that really one as you achieve proof-of-principle with the second gen pipeline or the next gen pipeline, that's the approach where you'll kind of take those programs through the DAYBREAK opportunity.

Question: Seamus Fernandez - Guggenheim Securities - Analyst : All right. Got it. Let's talk a little bit about just sort of the path of the company from here, the path to profitability or breakeven and what you see as sort of the key demarcation points along the way.

Question: Seamus Fernandez - Guggenheim Securities - Analyst : Great. Help us understand just that trajectory for HO. BBS, may be a little bit harder to identify the patients. Same thing with LEPR and POMC to some degree. This seems like the patients are identifiable, but I think rather than people getting over their skis and getting too excited that easily identifiable patient means patient treated immediately, maybe help us understand that that sort of path as we get there.

Question: Seamus Fernandez - Guggenheim Securities - Analyst : And we haven't talked about GLP-1s, the sort of general obesity product opportunities, and the various approaches that are starting to emerge there, can you just talk a little bit more about what is it that really differentiates the MC4 approach versus a GLP-1-based approach or amylin or something like that?

Question: Seamus Fernandez - Guggenheim Securities - Analyst : Great. Well, we only have 10 seconds left, so we're going to, move to wrap it up here. David, thank you so much for joining us and it's already been a fun ride, covering rhythm so far, so looking forward to many more successful years.